Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcutis Biotherapeutics Inc (NQ: ARQT )

8.320 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 37
Open 8.320
Bid (Size) 7.000 (1)
Ask (Size) 8.600 (4)
Prev. Close 8.320
Today's Range 8.320 - 8.320
52wk Range 1.760 - 15.21
Shares Outstanding 50,241,789
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Evaluating Arcutis Biotherapeutics: Insights From 5 Financial Analysts
Via Benzinga

Performance

YTD
+142.57%
+142.57%
1 Month
-14.05%
-14.05%
3 Month
+41.74%
+41.74%
6 Month
+269.78%
+269.78%
1 Year
-42.18%
-42.18%

More News

Read More
Arcutis Appoints David Topper as Chief Financial Officer
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Breaking Down Arcutis Biotherapeutics: 4 Analysts Share Their Views
Via Benzinga
Earnings Scheduled For February 27, 2024
Via Benzinga
Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) Leading the Way in Friday Trading Based on Percentage Gain
Via Investor Brand Network
EQT, Genie Energy And Other Big Stocks Moving Lower On Monday
Via Benzinga
Topics Stocks
Exposures US Equities
Arcutis Promotes Todd Tucker to Chief Human Resources Officer
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Announces Pricing of $150 Million Public Offering
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Announces Proposed Public Offering
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
MaxLinear Reports Q4 Results, Joins ING, Wolfspeed And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 Trial
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Verizon Posts Upbeat Earnings, Joins RTX, Procter & Gamble And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
iRobot, AST SpaceMobile And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.